C11orf47 Inhibitors
Inhibitors targeting the functional activity of C11orf47 include a range of compounds that act on various cellular and molecular pathways. These inhibitors are selected based on the assumption that C11orf47 is involved in or affected by these pathways. LY294002 and Wortmannin, for instance, inhibit the PI3K/AKT pathway, a critical signaling cascade that regulates cell survival and proliferation. If C11orf47 is an AKT substrate, the inhibition of PI3K would result in reduced phosphorylation and subsequent activity of C11orf47, as PI3K is upstream of AKT.
Similarly, compounds such as PD98059, U0126, SP600125, and SB203580 target the MAPK signaling cascade at different points. PD98059 and U0126 inhibit MEK, which is upstream of ERK1/2, while SP600125 and SB203580 specifically inhibit JNK and p38 MAPK, respectively. If C11orf47 is a downstream effector of one or more of these MAPKs, its activity would be diminished in the presence of these inhibitors due to reduced phosphorylation signals. Rapamycin's inhibition of mTOR signaling, which plays a central role in cell growth and metabolism, could similarly reduce the activity of C11orf47 if it is part of the mTOR signaling network.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can downregulate AKT signaling, potentially reducing the phosphorylation state of C11orf47 if it were AKT substrate. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that impairs the ERK pathway, which may reduce the activity of C11orf47 if it's regulated by ERK-mediated phosphorylation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that could decrease JNK-mediated phosphorylation of C11orf47, assuming C11orf47 is a JNK substrate. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor potentially reducing p38-mediated phosphorylation effects on C11orf47 if it is involved in the p38 MAPK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor which could prevent the activation of ERK, possibly leading to reduced activity of C11orf47 if ERK signaling affects its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that could lead to reduced AKT activity and potentially decrease the phosphorylation and activity of C11orf47 if it is an AKT target. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that could lead to reduced activity of C11orf47 if it's downstream of mTOR or part of mTORC1/C2 complexes. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Myosin II inhibitor that could disrupt cytoskeletal dynamics, possibly affecting C11orf47 if it interacts with the cytoskeleton or is regulated by mechanical stress. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Inhibitor of ADP-ribosylation factor which disrupts Golgi apparatus function, potentially affecting C11orf47 if it's involved in Golgi-related processes. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor leading to increased cytosolic calcium levels, which could decrease the activity of C11orf47 if it's regulated by calcium signaling. | ||||||